OPKO Health (OPK) Stock Price, News & Analysis

Company Overview

OPKO Health, Inc. is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions. Its products include Rayaldee, an extended-release formulation of calcifediol used to treat secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency. The company has also been involved in the development and commercialization of growth hormone therapies, including somatrogon, which is marketed in certain regions through a collaboration with Pfizer.

Headquartered in Miami, Florida, OPKO serves customers and patients in the United States and internationally through its laboratory, diagnostic and pharmaceutical activities. The company expanded its laboratory presence through the acquisition of Bio-Reference Laboratories in 2015. OPKO is led by Phillip Frost, who serves as executive chairman and chief executive officer.

Key Stats

• Today's Range: $1.55 to $1.58
• 50-Day Range: $1.24 to $1.73
• 52-Week Range: $0.98 to $1.75
• Volume: 1.40 million shs
• Average Volume: 2.27 million shs
• Market Capitalization: $1.16 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.55
• Consensus Rating: Hold

OPKO Health Stock Analysis - MarketRank™

OPKO Health scored higher than 21% of companies evaluated by MarketBeat, and ranked 779th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Hold

Consensus Rating

OPKO Health has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, 1 buy rating, 3 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for OPKO Health is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

OPKO Health has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for OPKO Health are expected to decrease in the coming year, from ($0.23) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OPKO Health is -17.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OPKO Health is -17.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OPKO Health has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.72% of the float of OPKO Health has been sold short.

Short Interest Ratio / Days to Cover

OPKO Health has a short interest ratio ("days to cover") of 10.55, which indicates bearish sentiment.

Change versus previous month

Short interest in OPKO Health has recently increased by 4.14%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OPKO Health does not currently pay a dividend.

Dividend Growth

OPKO Health does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.70

News Sentiment

OPKO Health has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for OPKO Health this week, compared to 4 articles on an average week.

Search Interest

Only 6 people have searched for OPK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added OPKO Health to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OPKO Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.72% of the stock of OPKO Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.63% of the stock of OPKO Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/27/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:OPK
• CIK: 944809
• Web: www.opko.com
• Phone: (305) 575-4100
• Fax: 305-575-6015
• Employees: 1,373
• Year Founded: 2007

Price Target and Rating

• Average Price Target for OPKO Health: $1.55
• High Price Target: $1.60
• Low Price Target: $1.50
• Potential Upside/Downside: -0.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$225.68 million
• Net Margins: -12.40%
• Pretax Margin: -13.58%
• Return on Equity: -5.88%
• Return on Assets: -3.83%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 3.35
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $606.90 million
• Price / Sales: 1.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 746,330,000
• Free Float: 412,570,000
• Market Cap: $1.16 billion
• Optionable: Optionable
• Beta: 1.51